Sino Biopharm unit CTTQ presents phase 3 APEX-Breast01 data for TQB2102 in HER2-low breast cancer at ESMO 2026

By Public Technologies
  • Sino Biopharmaceutical unit CTTQ will present new oncology trial data at ESMO 2026 in Madrid on Oct. 23, 2026.
  • Key readout covers APEX-Breast01, a phase 3 study comparing TQB2102 with chemotherapy in HER2-low recurrent or metastatic breast cancer.
  • Another presentation will update a phase 2 first-line gastric and gastroesophageal junction cancer study of TQB2102 combined with benmelstobart.
  • The update signals late-stage progress for TQB2102, a next-generation HER2 bispecific antibody-drug conjugate, ahead of potential commercialization steps.
  • CTTQ also flagged new clinical data for TQB2868, a PD-1/TGF-β bifunctional fusion protein, broadening its immuno-oncology pipeline narrative.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.